Primary analysis showed no significant evidence for a difference in time to end of target lesion primary patency between groups hazard ratio 1.18 with a 95% confidence interval of 0.78 to 1.79. There were no significant differences for any secondary outcomes, including patency outcomes and adverse events. Thus, our study demonstrated no evidence that paclitaxel-coated balloons provide benefit, following standard care high-pressure balloon angioplasty, in the treatment of arteriovenous fistulas. Hence, in view of the benefit suggested by other trials, the role of paclitaxel-coated angioplasty balloons remains uncertain.The hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, constitutes a serious complication of hepatic decompensation. Coexistence of liver/kidney damage, mentioned in the dropsy literature, was highlighted by Richard Bright in 1827 and confirmed in 1840 by his contemporary nephrology pioneer Pierre Rayer. Cholemic nephrosis was described in 1861 by Friedrich Frerichs, and the renal tubular lesions of HRS by Austin Flint in 1863. The term “acute hepato-nephritis” was introduced in 1916 by Paul Merklen, and its chronic form was designated HRS by Marcel Dérot in 1930s. NVP-ADW742 IGF-1R inhibitor HRS then was applied to renal failure in biliary tract surgery and to cases of coexistent renal and hepatic failure of diverse etiology. The pathogenesis of HRS was elucidated during the 1950 studies of renal physiology. Notably, studies of salt retention in edema and its relation to regulating the circulating plasma volume by John Peters and subsequently Otto Gauer defined the concept of “effective blood volume” and the consequent elucidation of ascites formation in liver failure. Parallel studies of intrarenal hemodynamics demonstrated severe renal vasoconstriction and preferential cortical ischemia to account for the functional renal dysfunction of HRS. Dialysis and liver or combined liver-kidney transplantation transformed the fatal HRS of old into a treatable disorder by the 1970s. Elucidation of the pathogenetic mechanisms of renal injury and refinements in definition, classification, and diagnosis of HRS since then have allowed for earlier therapeutic intervention with combined i.v. albumin and vasoconstrictor therapy, enabling the continued improvement of patient outcomes.Cerebrospinal fluid (CSF) diversion or shunting procedures are the most commonly performed surgery for the treatment of hydrocephalus and are often employed in the management of elevated intracranial pressure due to a variety of diseases. Despite their popularity however, approximately 50% of shunts fail within the first two years, and several revisions are required within the first decade after placement. Ophthalmologists may encounter patients with a CSF shunt to evaluate for concerns of vision loss or diplopia and to determine if papilledema is present. We discuss the neuro-ophthalmic manifestations and evaluation of possible CSF shunt malfunction.

Methods for p-value correction are criticized for either increasing Type II error or improperly reducing Type I error in large exploratory data analysis. This text considers patterns in probability vectors resulting from mass univariate analysis to correct p-values, where clusters of significant p-values may indicate true H0 rejection.

We used ERP experimental data from control and ADHD boys to test the method. The Log10 of p-vector was convolved with a Gaussian window whose length was set as the shortest lag above which autocorrelation of each ERP wave may be assumed to have vanished. We realized Monte-Carlo simulations (MC) to (1) evaluate confidence intervals of rejected and non-rejected areas of our data, (2) to evaluate differences between corrected and uncorrected p-vectors or simulated ones in terms of distribution of significant p-values, and (3) to empirically verify the type-I error rate (comparing 10,000 pairs of mixed samples whit control and ADHD subjects).

The differences between simulation or raw p-vector and corrected p-vectors were, respectively, minimal and maximal for window length set by autocorrelation in p-vector convolution.

Our method was less conservative while FDR methods rejected basically all significant p-values.The MC simulations presented 2.78 ± 4.83% of difference (20 channels) from corrected p-vector, while difference from raw p-vector was 596 ± 5.00% (p = 0.0003).

As a cluster-based correction, the present new method seems to be biological and statistically suitable to correct p-values in mass univariate analysis of ERP waves, which adopts adaptive parameters to correction.

As a cluster-based correction, the present new method seems to be biological and statistically suitable to correct p-values in mass univariate analysis of ERP waves, which adopts adaptive parameters to correction.

Brain MRI is a promising technique for Parkinson’s disease (PD) biomarker development. Its analysis, however, is hindered by the high-dimensional nature of the data, particularly when the sample size is relatively small.

This study introduces a folded concave penalized machine learning scheme with spatial coupling fused penalty (fused FCP) to build biomarkers for PD directly from whole-brain voxel-wise MRI data. The penalized maximum likelihood estimation problem of the model is solved by local linear approximation.

The proposed approach is evaluated on synthetic and Parkinson’s Progression Marker Initiative (PPMI) data. It achieves good AUC scores, accuracy in classification, and biomarker identification with a relatively small sample size, and the results are robust for different tuning parameter choices. On the PPMI data, the proposed method discovers over 80 % of large regions of interest (ROIs) identified by the voxel-wise method, as well as potential new ROIs.

The fused FCP approach is compared with L1, fused-L1, and FCP method using three popular machine learning algorithms, logistic regression, support vector machine, and linear discriminant analysis, as well as the voxel-wise method, on both synthetic and PPMI datasets. The fused FCP method demonstrated better accuracy in separating PD from controls than L1 and fused-L1 methods, and similar performance when compared with FCP method. In addition, the fused FCP method showed better ROI identification.

The fused FCP method can be an effective approach for MRI biomarker discovery in PD and other studies using high dimensionality data/low sample sizes.

The fused FCP method can be an effective approach for MRI biomarker discovery in PD and other studies using high dimensionality data/low sample sizes.